• DataMeds AI expanded a licensing partnership with Datavault AI to use its data monetization and real-world asset tokenization technology across commercial healthcare.
• The deal extends an earlier PharmacyChain-related license beyond pharmaceutical distribution into healthspan and wellness applications on the EinsteinRx platform.
• Datavault AI is set to receive common shares equal to about 19.9% of DataMeds’ common stock at closing, replacing preferred shares.
• The share issuance is contingent on closing related transactions, including acquisitions tied to QOLPOM IP portfolios and a controlling stake in Tollo Health.
• DataMeds plans to use the technology for patient-controlled health data access and data-transaction models across pharmacy, medical, lab, and wearables settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DataMeds AI Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607291015ACCESSWRNAPR_____1197984) on July 29, 2026, and is solely responsible for the information contained therein.